Heart disease, type 2 diabetes, high blood pressure and obesity were more common and linked to reduced ... The study is ...

The intricate relationship between diet, metabolic disorders, and cancer progression has garnered significant attention in recent years. Excessive calorie intake is known to trigger the production of ...

Whose White House wardrobe comes out on top? We delve into the sartorial archives of history's fabulous First Ladies ...

Real-world data showed mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity (N=8) at three months on setmelanotide ...

After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 ...

Two presentations to highlight increased weight loss in obese mice treated with azelaprag in combination with multiple oral appetite suppressants, and significant protection against weight gain with ...

Title: Novel Oral Small Molecule Dual Amylin and Calcitonin Receptor Agonists for Obesity Treatment Poster Number: Poster 128 Date/Time: Sunday, November 3, 7:30 p.m. – 8:30 p.m. CT Location: Exhibit ...

Research shows that restricting fast-food outlets can lower obesity rates in children, highlighting the role of planning ...

The league will have court designs made specifically for the NBA Cup again this year, and presented them Thursday. The courts will look different this time around. They will be slightly more ...

Diwali is a time to celebrate light, joy, and togetherness, and one way to enhance this festive atmosphere is by creating beautiful rangoli designs. This year Diwali will be celebrated on Friday ...

CINCINNATI--(BUSINESS WIRE)--CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity, will present two posters at ObesityWeek ...

About CIN-109: CIN-109 is a Phase 2 ready, a novel, long-acting, first-in-class growth differentiation factor 15 (GDF-15) analog for the treatment of obesity. CIN-109 is a Phase 2 ready candidate ...